Amgen "market perform"

26.06.07 - Rodman & Renshaw

NEW YORK, June 26 (newratings.com) - Analyst Michael G King Jr of Rodman & Renshaw maintains his "market perform" rating on Amgen Inc (AMGN).

In a research note published yesterday, the analyst mentions that the key competitors to the company?s drugs include Mircera, which is administered once a month and keeps the hemoglobin level stable with less erratic excursions in the high risk kidney patients, who also suffer from diabetes and heart disease. If Mircera is approved, it would directly compete against Amgen?s Aranesp and Epogen drugs, the analyst says.